Is an IP Lawyer with especial focus on licensing and monetisation strategy and has worked in the sector for over 30 years, largely in private practise here in the UK as principal of his business ISS and as Counsel for EEE Group.He holds an LLB (Hons) in law, an M.Phil (summa cum lauda) in international licensing and is Chair and Fellow of the Institute of Intellectual Property Licensing; F.I.I.L.P.He is currently Vice-Chair of IPAN the all sector Intellectual Property Awareness Network which is representative of respectively: academia; commerce; industry and; many related professions, whose mission is the better promotion and understanding of IP.He has been Sometime Lecturer in IP Licensing at Brunel University of London and published widely on all matters related to the exploitation of IP assets.

Caroline is an accomplished Ex-Medical Practitioner who has developed growth and innovation strategies for private and public companies in North America, Europe and Asia. During a 10-year career at Becton Dickinson (NYSE: BDX), Dr. Popper’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene, an internal start-up focused, with its partner Millennium Pharmaceuticals, on development of novel molecular diagnostics. She was subsequently responsible for Diagnostic Strategy at bioMerieux and thereafter was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the U.S., Canada and Europe. She has founded several companies in diagnostics and pharma services and participates as an independent director on several company boards. She received her medical degree from the University of the Witwatersrand (South Africa) and her M.P.H. from Johns Hopkins University (Baltimore). Caroline shall be heading our DC office while Charles continues to head our UK operations.

Chi has been serving as Negin’s Executive Assistant for years, providing her with all her Executive briefings before every meeting. Chi obtained her Master’s Degree with Distinction in Banking and Finance from the University of Nottingham. Chi is continuously engaged in Banking Risk Management and prior to serving as Negin’s EA, she had worked in Banking Supervision and Sales Management. She has an eye for details and is extremely up to date with IMF and the regulatory framework applying to our sectors of investments.

Minh serves as Charles’ Personal Assistant at EEE and is instrumental in conducting research on a short timescale. Minh achieved her Master's Degree with Distinction in Banking and Finance from the University of Nottingham. Before joining EEE, Minh had been a Credit Analyst with experience working alongside the Executive team of one of the largest banks in the world. She has obtained a MCBI/Chartered Banker's certificate which are truly complemented by her skills and experiences in Retail/Wholesales Banking. She has also completed thorough training on IP Diligence under EEE's Head of IP.

Dr. Carrie Kuehn is a talented medical device regulatory and clinical affairs professional with a diverse background and over 25 years of experience in research epidemiology, medical devices, regulatory and clinical affairs, and patient-focused policy. In practice, Dr. Kuehn applies her expertise, leadership, strategic remediation skills, and broad medical device clinical-regulatory knowledge to address the needs of medical products companies and stakeholders across therapeutic areas. Dr. Kuehn excels at taking complex, multidisciplinary problems and synthesizing them into a cohesive strategy. She is particularly skilled at stepping into crises, supporting remediation efforts, conducting gap analyses, reorienting strategic plans, and bringing positive results out of fire-drill situations. Dr. Kuehn applies her adaptable skill set to address complex issues in the pre-market and post-market space to enhance compliance, fine tune business practice, and improve patient lives around the world. With the increase in clinical requirements being imposed on medical device companies globally, Carrie can provide critical expertise in real-world evidence generation, regulatory affairs, and observational and clinical research methods, execution, and publication of clinical results to achieve and maintain market authorization. An accomplished researcher, Dr. Kuehn has published in the areas of epidemiology, regulatory affairs, and patient engagement policy. She also maintains a blog covering topics relevant to medical regulatory affairs practice and patient-focused policy. As faculty in the RAQA Graduate Program at Temple University and in the Regulatory Affairs Graduate Program at the Hong Kong University of Science and Technology, Dr. Kuehn helps to prepare the next generation of patient-focused, medical device regulatory professionals

Dr. Langdon serves as EEE Medical Advisory Committee Member specializing in Obstetrics and Gynecology. She is a retired, board-certified obstetrician/gynecologist with 19-years of clinical experience. She graduated from The Ohio State University College of Medicine, earning Honors in many rotations. She then completed her OB/GYN residency program at The Ohio State University Medical Center where she earned first place in her Senior research project and finished in the 98th percentile on a national proficiency test in OB/GYN, specializing in minimally invasive procedures, menopause, endometriosis, menstrual disorders, and polycystic ovarian syndrome. She is a medical writer, medical reviewer, and featured healthcare expert. Dr. Langdon serves as a partner for EEE, leading on Military gynecological applications.

Dr. Datt serves as EEE Medical Advisory Committee Member specializing in Neurology, Rare paediatric diseases, and Neurodevelopmental clinics, including mental health disorders such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Dr. Datt has undertaken extensive research on various rare paediatric diseases, including conditions like Mucopolysaccharidoses (MPS), paediatric multiple sclerosis, haemophilia, sickle cell anaemia, betathalassaemia, X-linked hypophosphatemia (XLH), Vitamin D deficiency, Achondroplasia, Primary Immunodeficiencies (PID), and various paediatric cancers. In addition to being a skilled doctor, Dr. Datt is also an educational supervisor with the General Medical Council (GMC), postgraduate tutor, and board examiner with the Faculty of Pharmaceutical Medicine (FPM). He is passionate about providing client-focused care and raising awareness about rare paediatric conditions while providing medical education. Dr. Datt completed a degree in Biological Medicinal Chemistry with Drug Design (BSc.), a post graduate Diploma in Pharmaceutical Medicine from Oxford, and graduated from Medical School (MBBS) from the University of East Anglia. He has also undertaken postgraduate certificates and diplomas in Child Health and conducted research in gastroesophageal reflux disease, and leukaemia at the National Institute for Health (NIH) in Maryland, USA. He has been awarded a Fellowship of the Faculty of Pharmaceutical Medicine by the Fellowship and Awards Committee.

Dr. Samimi serves as EEE Pre-FDA Submissions Regulatory Advisor. He is a highly-cited physicist, medical device expert, and market entry strategist. He has led systems engineering efforts from concept to manufacturing and driven FDA clearance for several pioneering medical devices, including one of the first point-of-care MR systems for brain imaging, remote-patient monitoring devices, robotic dental surgery systems and AI-powered ECGs for cardiac diagnostics. Dr. Samimi brings cross-industry experience to the medical device sector, with past collaborations on submarine hull inspection technologies with Defence Canada (DRDC) and electric motor energy efficiency with General Motors (GM) and the Fraunhofer Institute in Germany. Previously, he worked at StarFish Medical, partnering with VC-backed clients in California and Boston to drive business growth. He now focuses on physician-led innovation and clinically-backed technologies. His recent work includes helping clients launch transformative medical devices by managing FDA communications, ensuring investment readiness, and developing market entry strategies. Dr. Samimi holds a PhD in Physics from Queen's University in Canada. Dr. Samimi serves as a partner for EEE for VC-backed medical device startups.

Dr. Al-Memar serves as EEE Medical Advisory Committee Member and he is a Senior NHS Consultant Neurologist with over two decades of experience in the field of neuromuscular disorders. Dr. Al-Memar is one of the most sought after medical specialists in London, United Kingdom. Dr. Al-Memar is based at Kingston Hospital NHS Foundation Trust, Concierge hospital. He is also the CEO and Founder of luxury Medical facilities: Ascot Rehab and New Malden Diagnostic Center. Dr. Al-Memar serves as a partner for EEE, specializing in Neuromuscular Disorders.

Mr. Holt serves as EEE Med-Tech Patent Advisor specializing in significant contentious patent matters. Mr. Holt focusses on the biotechnology, Med-Tech, synthetic biology and cancer therapeutics sectors, with a major part of his practice involving novel therapeutics. He leads Potter Clarkson’s IP Due Diligence practice and has experience in a wide range of Due Diligence projects ranging from seed investments through to Series B transactions. Mr. Holt has particular expertise in drafting highly complex, multi-jurisdictional agreements including licensing arrangements, research and development agreements and complex collaboration agreements, as well as providing commercially focused IP strategy advice. This expertise has also led to his involvement in the organizing committee of the Licensing Executives Society (Britain & Ireland) YMC, and has recently led a panel at the LESI Britain & Ireland annual meeting in relation to the importance of effective spin-out of technology from Universities in generating economic success. Mr. Holt serves as a partner for EEE.

Mr. Carling serves as EEE Pharmaceutical Patent Advisor specializing in patent groups with a primary focus on inventions in the fields of medicine, chemistry and food technology. In addition to drafting and prosecuting chemical and pharmaceutical patent applications, he regularly co-ordinates worldwide patent strategies and conducts patent oppositions on this technology. Mr. Carling also has expertise in patent term extensions and regulatory exclusivity, particularly specializing in supplementary protection certificates (SPCs) - a form of IP that can provide an additional monopoly period beyond patent expiry for some medicinal and plant protection products. Prior to joining Potter Clarkson, he obtained a PhD from the University of Nottingham, and spent two years working in regulatory affairs specializing in industrial chemicals and biocidal substances.  Mr. Carling serves as a partner for EEE.

Christopher Burns is an experienced investor relations professional with 18 years of international experience in investing, consulting and relationship management across alternative assets. Christopher leads investor relations for EEE Group, managing fundraising activities for our portfolio companies, primarily comprising private individuals and family offices, as well as venture capital and private equity funds. He originally began as an investor relations senior associate, servicing EEE from our London office in September 2020.